Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
601 vs Ranibizumab in pmCNV
NCT04922151Phase 2Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 601 in pathological myopic choroidal neovascularization (mCNV), sponsored by 3S Guojian Pharmaceutical. Status: unknown.
02
Drugs
601
03
Conditions
pathological myopic choroidal neovascularization (mCNV)
Beyond the preview
Go deeper on NCT04922151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922151.